In a patient with COPD and acute exacerbation, which of the following is the most appropriate initial antibiotic choice for community-acquired infection in the absence of severe disease or recent hospitalization?

Explanation

## Antibiotic Selection in COPD Exacerbation (Non-Severe, Community-Acquired) **Key Point:** In acute exacerbation of COPD (AECOPD) with community-acquired infection and **no severe disease or recent hospitalization**, the most appropriate initial antibiotic choice is **amoxicillin-clavulanate or an oral cephalosporin** (Option B). This is consistent with GOLD 2023, NICE, and ERS guidelines, which reserve respiratory fluoroquinolones for more severe disease, risk of *Pseudomonas*, or failure of first-line agents. **High-Yield:** First-line agents for non-severe AECOPD cover the three most common bacterial pathogens: - *Haemophilus influenzae* - *Streptococcus pneumoniae* - *Moraxella catarrhalis* Amoxicillin-clavulanate and oral cephalosporins (e.g., cefuroxime, cefpodoxime) provide excellent coverage against these organisms, including beta-lactamase-producing strains, and are preferred as initial empirical therapy in uncomplicated cases. ## Antibiotic Hierarchy in AECOPD | Scenario | First-Line | Alternative | Avoid | | --- | --- | --- | --- | | Non-severe, community-acquired | Amoxicillin-clavulanate or oral cephalosporin | Macrolide (if low resistance risk) | Carbapenem; fluoroquinolone (reserve) | | Severe or recent hospitalization / fluoroquinolone-preferred | Respiratory fluoroquinolone (levofloxacin/moxifloxacin) | Beta-lactam + macrolide | Monotherapy with weak agents | | Pseudomonas risk (prior isolation, severe disease) | Anti-pseudomonal fluoroquinolone (ciprofloxacin) or piperacillin-tazobactam | Carbapenem if severe | Standard fluoroquinolones | | Hospitalized, ICU | Broad-spectrum IV: beta-lactam + fluoroquinolone ± aminoglycoside | Carbapenem if resistant organisms | Monotherapy | **Clinical Pearl:** Respiratory fluoroquinolones (levofloxacin, moxifloxacin) are **not** universally first-line for all AECOPD. GOLD 2023 and NICE guidelines recommend reserving them for: - Patients with severe exacerbations - Recent hospitalization or antibiotic use - Risk of *Pseudomonas aeruginosa* - Failure of first-line beta-lactam therapy This stewardship approach limits fluoroquinolone overuse and reduces the risk of *C. difficile* infection, tendinopathy, and resistance selection. **Warning:** Macrolide monotherapy (azithromycin) is not recommended as first-line due to increasing resistance in *H. influenzae* and *S. pneumoniae*. Carbapenem (meropenem IV) is inappropriate for non-severe, community-acquired AECOPD. [cite: GOLD 2023 Report, Chapter 5; NICE NG115 (2019); Harrison's Principles of Internal Medicine 21e, Ch. 254]